BACKGROUND: Ampullary carcinoma is a rare malignancy. Despite radical resection, survival rates remain low with high rates of local failure. We performed a single-institution outcomes analysis to define the role of concurrent chemoradiotherapy (CRT) in addition to surgery. METHODS: A retrospective analysis was performed of all patients undergoing potentially curative pancreaticoduodenectomy for adenocarcinoma of the ampulla of Vater at Duke University Hospitals between 1976 and 2009. Time-to-event analysis was performed comparing all patients who underwent surgery alone to the cohort of patients receiving CRT in addition to surgery. Local control (LC), disease-free survival (DFS), overall survival (OS), and metastases-free survival (MFS) were estimated using the Kaplan-Meier method. RESULTS: A total of 137 patients with ampullary carcinoma underwent Whipple procedure. Of these, 61 patients undergoing resection received adjuvant (n = 43) or neoadjuvant (n = 18) CRT. Patients receiving chemoradiotherapy were more likely to have poorly differentiated tumors (P = .03). Of 18 patients receiving neoadjuvant therapy, 67% were downstaged on final pathology with 28% achieving pathologic complete response (pCR). With a median follow-up of 8.8 years, 3-year local control was improved in patients receiving CRT (88% vs 55%, P = .001) with trend toward 3-year DFS (66% vs 48%, P = .09) and OS (62% vs 46%, P = .074) benefit in patients receiving CRT. CONCLUSIONS: Long-term survival rates are low and local failure rates high following radical resection alone. Given patterns of relapse with surgery alone and local control benefit in patients receiving CRT, the use of chemoradiotherapy in selected patients should be considered.
BACKGROUND:Ampullary carcinoma is a rare malignancy. Despite radical resection, survival rates remain low with high rates of local failure. We performed a single-institution outcomes analysis to define the role of concurrent chemoradiotherapy (CRT) in addition to surgery. METHODS: A retrospective analysis was performed of all patients undergoing potentially curative pancreaticoduodenectomy for adenocarcinoma of the ampulla of Vater at Duke University Hospitals between 1976 and 2009. Time-to-event analysis was performed comparing all patients who underwent surgery alone to the cohort of patients receiving CRT in addition to surgery. Local control (LC), disease-free survival (DFS), overall survival (OS), and metastases-free survival (MFS) were estimated using the Kaplan-Meier method. RESULTS: A total of 137 patients with ampullary carcinoma underwent Whipple procedure. Of these, 61 patients undergoing resection received adjuvant (n = 43) or neoadjuvant (n = 18) CRT. Patients receiving chemoradiotherapy were more likely to have poorly differentiated tumors (P = .03). Of 18 patients receiving neoadjuvant therapy, 67% were downstaged on final pathology with 28% achieving pathologic complete response (pCR). With a median follow-up of 8.8 years, 3-year local control was improved in patients receiving CRT (88% vs 55%, P = .001) with trend toward 3-year DFS (66% vs 48%, P = .09) and OS (62% vs 46%, P = .074) benefit in patients receiving CRT. CONCLUSIONS: Long-term survival rates are low and local failure rates high following radical resection alone. Given patterns of relapse with surgery alone and local control benefit in patients receiving CRT, the use of chemoradiotherapy in selected patients should be considered.
Authors: J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils Journal: Ann Surg Date: 1999-12 Impact factor: 12.969
Authors: John P Duffy; Oscar J Hines; Jerome H Liu; Clifford Y Ko; Galen Cortina; William H Isacoff; Henry Nguyen; Michael Leonardi; Ronald K Tompkins; Howard A Reber Journal: Arch Surg Date: 2003-09
Authors: John T Miura; Thejus T Jayakrishnan; Albert Amini; Fabian M Johnston; Susan Tsai; Beth Erickson; Edward J Quebbeman; Kathleen K Christians; Douglas B Evans; T Clark Gamblin; Kiran K Turaga Journal: J Gastrointest Surg Date: 2014-08-27 Impact factor: 3.452
Authors: Ibrahim Nassour; Linda S Hynan; Alana Christie; Rebecca M Minter; Adam C Yopp; Michael A Choti; John C Mansour; Matthew R Porembka; Sam C Wang Journal: J Gastrointest Surg Date: 2017-11-10 Impact factor: 3.452
Authors: Matthew P Doepker; Zachary J Thompson; Barbara A Centeno; Richard D Kim; Joyce Wong; Pamela J Hodul Journal: J Surg Oncol Date: 2016-05-09 Impact factor: 3.454
Authors: Jim Zhong; Manisha Palta; Christopher G Willett; Shannon J McCall; Frances McSherry; Douglas S Tyler; Hope E Uronis; Brian G Czito Journal: J Gastrointest Oncol Date: 2014-12
Authors: Daniel Weiss Vilhordo; Cleandra Gregório; Dirceu Felipe Valentini; Maria Isabel Albano Edelweiss; Diego Mendonça Uchoa; Alessandro Bersch Osvaldt Journal: J Gastrointest Cancer Date: 2021-09
Authors: Jim Zhong; Manisha Palta; Christopher G Willett; Shannon J McCall; Anuradha Bulusu; Douglas S Tyler; Rebekah R White; Hope E Uronis; Theodore N Pappas; Brian G Czito Journal: J Gastrointest Oncol Date: 2013-03
Authors: Suguru Yamashita; Michael J Overman; Huamin Wang; Jun Zhao; Masayuki Okuno; Claire Goumard; Ching-Wei Tzeng; Michael Kim; Jason B Fleming; Jean-Nicolas Vauthey; Matthew H Katz; Jeffrey E Lee; Claudius Conrad Journal: Ann Surg Oncol Date: 2017-10-04 Impact factor: 5.344